New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
06:50 EDTBIO, BIOBio-Rad upgraded to Outperform from Underperform at CLSA
CLSA upgraded Bio-Rad based on earnings leverage, consistent diagnostics growth, ERP completion, easier currency comps, and exposure to Asia. Price target raised to $124 form $103
News For BIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2015
16:34 EDTBIOBio-Rad announces FDA pre-market approval for BioPlex 2200 HIV Ag-Ab assay
Subscribe for More Information
July 23, 2015
15:02 EDTBIOFDA approves Bio-Rad HIV differentiation diagnostic test
The FDA announced it has approved the Bio-Rad BioPlex 2200 HIV Ag-Ab assay, the first FDA-approved diagnostic that differentiates between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens. The BioPlex 2200 HIV Ag-Ab assay is intended for use with the BioPlex 2200 System, which was cleared by the FDA in 2004. The new assay is manufactured by Bio-Rad Laboratories.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use